Dr. Fletcher founded and serves as CEO of Bios Research, a financial services firm that provides public equity research in the healthcare space tailored to institutional firms and large family offices. Bios Research provides fundamental healthcare industry research focused in the biotech and med-tech sub-sectors and through this research Dr. Fletcher has a strong understanding of commercial viability in the marketplace. Dr. Fletcher holds a PhD in Biochemistry from Colorado State University, and serves as a professor at Dallas Baptist University where he teaches Biochemistry, Bioethics, and Cell Biology. Dr. Fletcher has worked as an independent consultant for the biotech/healthcare equity industry for over 10 years.
Alex is the Chief Research and Development Officer of Kairos Ventures where he is responsible for all aspects of deal sourcing, deal vetting, due diligence, and investment recommendation. Alex joined Kairos Ventures with 20+ years of experience at high-tech companies specializing in enterprise software, ranging in size from startups with a handful of employees to behemoths with tens of thousands of employees. In these companies, Alex led global teams of dozens of employees responsible for product strategy, intellectual property protection, engineering, professional services, sales, marketing, and business development, and actively participated in the efforts to close, and successfully closed, multiple rounds of financing by venture capital firms as well as the public markets. Before joining Kairos Ventures, Alex led the business development efforts for AtScale, an enterprise software company. Previous to that, he was the global Chief Marketing Officer for Guidance Software, a public corporation specializing in cybersecurity and digital forensics (now owned by OpenText). During his tenure at Oracle, Alex led the research and strategic alignment efforts for numerous acquisitions ranging in value from a few tens of millions to billions of dollars. Alex has a degree in Electrical Engineering with a specialization in Computer Engineering and an MBA in Finance and Marketing.
Neil Bajpayee, Ph.D. is a Board Member of Actuate Therapeutics and an Investment Associate at Kairos Ventures, a venture capital firm based in Los Angeles. At Kairos, Dr. Bajpayee is responsible for sourcing and evaluation of life science opportunities, and he serves as an Observer or Member of the Board for 4 portfolio companies. Prior to Kairos, Dr. Bajpayee was the Director of Business Development at Trethera Corporation, an oncology startup in Los Angeles, where he managed all partnerships, led the in-licensing of the company’s clinical- and preclinical-stage assets, as well as supported nonclinical drug development activities. Previously, Dr. Bajpayee was a licensing officer at UCLA’s Office of Intellectual Property where he managed licensing, marketing, and IP strategy for biomedical inventions emanating from the university.
Dr. Bajpayee received a Ph.D. in Molecular & Medical Pharmacology from the University of California, Los Angeles. He received his B.S. in Microbiology from Pennsylvania State University.
Mr. Les Kreis is the Principal at Steelhead Capital Management, a private equity firm based in Fort Worth, TX, which invests in early seed opportunities as well as later stage growth companies, with a primary focus on technology, energy, pharmaceuticals and consumer packaged goods. Mr. Kreis also serves as a Member of the Cowtown Angels investment group and the Portfolio Advisory Board at Texas Women Ventures.
Mr. Schmitt brings 30 years of successful industry experience in operations management, new product development, and business development, having held senior executive positions in both large pharmaceutical and small biotechnology companies, including Fujisawa, Searle / Pharmacia, and Ilex Oncology. During his career, Daniel has led and contributed to the successful development and launch of over 12 pharmaceutical products, and has constructed and executed numerous high value licensing, acquisition, and development deals for biotech and pharmaceutical companies totaling nearly $1 billion in upfront and potential milestone payments.
Mr. Schmitt received his M.B.A and a B.S. in Chemistry and Theoretical Mathematics from West Virginia University, and has held research positions affiliated with the National Foundation for Cancer Research and at the University of North Carolina School of Medicine. He serves as an Entrepreneur-in-Residence at Northwestern University, and as an external expert consultant for the University of Chicago and the University of Illinois-Chicago. Mr. Schmitt is also a founding member of Chicago Innovation Mentors.